Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time


Business Wire | Feb 11, 2021 04:30PM EST

Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time

Feb. 11, 2021

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 11, 2021--Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 4:30 p.m. ET on Thursday, February 25, 2021, to discuss its financial and operating results for the fourth quarter and full year of 2020.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1?678-509-7599 (international callers) and provide passcode 5247866. A live webcast will also be available in the Investors section of the Company's website at www.lantheus.com.

A replay of the webcast will be available in the Investors section of the Company's website approximately two hours after completion of the call and will be archived for 30 days.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow(tm) serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY(r) Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite(r) (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA(r) for the treatment of certain rare neuroendocrine tumors; and RELISTOR(r) for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005736/en/

CONTACT: Contacts: Mark Kinarney Senior Director, Investor Relations 978-671-8842 ir@lantheus.com

CONTACT: Melissa Downs Director, Corporate Communications 646-975-2533 media@lantheus.com






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC